Thank you to the attendees, faculty, sponsors, and supporters of the Psychopharmacology Update for making the conference a tremendous success!  We hope to see you again in 2020. SIGN UP for email updates to keep informed of program developments for our upcoming conference as they become available.



The American Board of Psychiatry and Neurology has reviewed the 2019 Psychopharmacology Update and has approved this program as part of a comprehensive CME program, which is mandated by the ABMS as a necessary component of maintenance of certification (MOC). The activity awards 11.5 AMA PRA Category 1 CreditsTM and 5.5 Self-Assessment Category 1 CME credits.

Overview of the 18th Annual Psychopharmacology Update

This well-established one-day CME symposium offers an outstanding opportunity for education and networking with minimal disruption to your busy schedule. At this full-day course, nationally renowned faculty will cover Recent Breakthroughs in Psychopharmacology: Novel Treatments. New for this year are pre-conference workshops on addiction and medical cannabis. You will get in-depth analysis from our expert faculty and ample time to query them on topics that will help keep your practice ahead of the curve.

Who Should Attend:

The 2019 Psychopharmacology Update is a CME conference designed for child and adolescent psychiatrists, general psychiatrists, geriatric psychiatrists, neuropsychiatrists, pharmacists, nurse practitioners, physician assistants, nurses, psychologists, social workers, and other mental health professionals interested in treating patients with psychiatric disorders to remission with measurement-based care.

Continuing Medical Education

Physician Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Global Academy for Medical Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

The University of Cincinnati designates this Live Activity for a maximum of 11.5 AMA PRA Category 1 CreditsTM (5.5 for the general program and 6 AMA PRA Category 1 Credits™ for completing the pre-conference workshops. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants Credit Designation

The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 CreditsTM from organizations accredited by the ACCME.


Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 11.5 (5.5 for the general sessions and 6 for attending the pre-conference workshops) contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses has been designated for 2.1 contact hours and will be indicated on your certificate.

At the conclusion of this activity, clinicians should be better able to:

  • Explain the neurobiology of addiction and how it can inform treatment.
  • Describe special needs and issues related to the pregnant addicted patient, adolescent and elderly addicted populations, and patients with comorbid psychiatric disorders.
  • Describe the pharmacology of cannabis and the formulations used for medical purposes.
  • Discuss current state of the evidence for the therapeutic use of cannabis.
  • Review acute and chronic risks of cannabis use.
  • Develop strategies to implement medical cannabis safely and effectively into clinical practice.
  • Increase routine screening to identify women with perinatal or postpartum depression.
  • Develop treatment strategies for women diagnosed with postpartum depression.
  • Discuss the clinical efficacy and safety data regarding glutamatergic agents (such as ketamine and esketamine) as a novel treatment option for patients with treatment-resistant depression (TRD).
  • Describe the similarities and differences between the available LAI antipsychotic agents.
  • Review the pertinent history of research into psychedelic agents as it pertains to their role in managing psychiatric conditions.
  • Describe the mechanism of action of psilocybin and MDMA and their safety data.
  • Discuss the state of current research into psychedelic agents and their progress through clinical trials.
  • Assess patients with psychiatric disorders for common risk factors for tardive dyskinesia.
  • Identify the similarities and differences between FDA-approved VMAT2-inhibitors for tardive dyskinesia.
  • Identify strategies to manage clozapine-resistant schizophrenia.
  • Describe clinical findings of pimavanserin in the management of clozapine-resistant schizophrenia.
  • Review screening and diagnostic assessment approaches for Parkinson’s disease psychosis
  • Select an optimal treatment strategy for patients with Parkinson’s disease psychosis.

International Credit Designation

European physicians can earn their ECMEC®s by attending live events worldwide that have been granted ECMEC®s through the UESMS-EACCME procedure, and worldwide, except in Europe, that have been certified for AMA PRA Category 1 Credits™. European physicians can also earn their ECMEC®s by completing e-learning programs from providers from all over the world except in the United States, that have been granted ECMEC®s through the UEMS-EACCME procedure and from accredited providers from the United States, that have been certified for AMA PRA Category 1 Credits™.

Additionally, the following countries and regions have reciprocity with the ACCME:

  • Bulgarian Union of Scientific Medical Societies (Bulgaria)
  • Federation of Royal Colleges of Physicians (UK)
  • French National Medical Council (France)
  • Italian Federation of Scientific Medical Societies (Italy)
  • National CME Commission of the Italian Ministry of Health (Italy)
  • Royal College of Physicians and Surgeons of Canada (Canada)
  • Spanish Accreditation Council for CME (Spain)
  • Bavarian Chamber of Physicians (Germany)


Follow Us

Jointly Provided By